About XORTX Therapeutics Inc. - Common Stock (XRTX)
Xortx Therapeutics Inc is a biotechnology company dedicated to developing innovative therapies for kidney-related conditions, particularly focused on diseases such as chronic kidney disease and metabolic disorders. The company aims to address significant unmet medical needs by advancing its proprietary drug candidates through clinical trials and bringing novel solutions to patients suffering from these challenging health issues. By leveraging advancements in science and technology, Xortx is committed to improving the quality of life for individuals impacted by kidney diseases. Read More
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million.
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
New York, NY - March 19, 2024 - In the realm of pharmaceutical innovation, XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), stands out for its significant achievements in 2023 and ambitious plans for 2024. XORTX, a late-stage clinical pharmaceutical firm specializing in revolutionary treatments for progressive kidney disease, has made headlines with its tremendous progress.
New York, NY, March 19, 2024 – (Plato Data) -- In the realm of pharmaceutical innovation, XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), stands out for its significant achievements in 2023 and ambitious plans for 2024. XORTX, a late-stage clinical pharmaceutical firm specializing in revolutionary treatments for progressive kidney disease, has made headlines with its tremendous progress.
Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates.
